Alkermes announced that it has completed the separation of its oncology business into Mural Oncology, a new, independent, publicly traded company. Alkermes is now a pure-play, profitable neuroscience company that will continue its work to develop innovative medicines for people living with difficult-to-treat psychiatric and neurological disorders. Mural Oncology will begin “regular way” trading on the Nasdaq Global Market under the stock ticker symbol “MURA” on Nov. 16, 2023. Alkermes will continue to trade under the Nasdaq ticker symbol “ALKS.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALKS:
- Alkermes management to meet with Piper Sandler
- Alkermes: SEC declares Form 10 registration statement filed by Mural effective
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Biotech Alert: Searches spiking for these stocks today
- Alkermes price target lowered to $35 from $37 at Mizuho